Navigation Links
Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
Date:10/7/2008

SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that a poster entitled "RDEA119, a Potent and Highly Selective MEK1/2 Inhibitor is Beneficial in Dextran Sulfate Sodium (DSS) -- induced Chronic Colitis in Mice," was presented at the American College of Gastroenterology (ACG) 2008 Annual Meeting in Orlando, Florida. The poster, which provided data from a preclinical study of RDEA119, the Company's lead mitogen-activated ERK kinase (MEK) inhibitor, showed the product candidate to be a promising investigational therapy for inflammatory diseases.

Oral administration of RDEA119 was shown to significantly reduce damage to colonic tissue and disease activity in dextran sulfate sodium (DSS) -- induced chronic colitic mice. The beneficial effect of RDEA119 exceeded that of Remicade(R) (infliximab), the current standard-of-care for the treatment of ulcerative colitis.

"Blocking the MEK1/2 pathway appears to be a promising strategy for treating inflammatory disease, for which a significant unmet medical need still exists," commented Dr. Barry Quart, PharmD, president and chief executive officer. "We are making excellent progress with our programs addressing inflammatory disease and the data presented today demonstrate the potential of our MEK inhibitors, RDEA119 and our second generation MEK inhibitor, RDEA436, as treatments for these diseases, and support our continued efforts in this area."

Earlier this year, the Company successfully completed a Phase 1 study of RDEA119 in healthy volunteers in which the product candidate demonstrated a long half-life and a favorable pharmacokinetic profile. The Company plans to initiate a Phase 1b clinical trial of RDEA119 in gouty arthritis l
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
2. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
3. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
4. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
5. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
6. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
7. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
10. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
11. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015  Dohmen Company CEO ... for the Metropolitan Milwaukee Association of Commerce,s annual ,Future ... at the Pfister Hotel. The ,Future 50, Awards highlights ... businesses and young firms headquartered in the seven-county ... has called Milwaukee home for ...
(Date:9/4/2015)... , Sept. 4, 2015  Luminex Corporation (NASDAQ: ... the Morgan Stanley Global Healthcare Conference to be held ... Hotel in New York City . ... a.m. Eastern time on Friday, September 18, 2015.  The ... Luminex Corporation,s website at http://www.luminexcorp.com . Simply log on ...
(Date:9/4/2015)... According to a new market ... Leukapheresis, and Photopheresis) by Procedure (Therapeutic Apheresis, Donor Apheresis/Apheresis ... Forecast to 2020", published by MarketsandMarkets, the global Apheresis ... 2020, growing at a CAGR of 11.2% during the ... Browse 139 Tables and 45 F igures spread ...
Breaking Medicine Technology:Dohmen CEO Cynthia LaConte to Keynote MMAC 'Future 50' Awards Luncheon 2Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5
... NEW YORK, June 2, 2011 Citeline, the world,s ... recently completed a comprehensive review of clinical trial starts ... patterns in drug development. Over the one-year review period ... trials were initiated in the oncology sector, more than ...
... Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today ... Trademark Office of Patent Application Serial No. 12/549458 ... This follows the UK issuance which was granted ... patent estate. The patent covers the ...
Cached Medicine Technology:Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase 2Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase 3Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat 2Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat 3
(Date:9/4/2015)... ... ... Having access to a doctor can sometimes be a challenge for a variety of ... which affects hospitals’ abilities to provide quality service to those with serious needs, increases ... problem has recently presented itself, the new telemedicine platform and app, DocChat . ...
(Date:9/4/2015)... ... , ... Lalonde Gordon ran a 44.64 seconds scorcher in the third and ... 400 meters final, with an impressive 44.89 seconds at the 2015 North American, Central ... in August 2015. The 44.64 time is a new NACAC Championship record. , ...
(Date:9/4/2015)... Washington, DC (PRWEB) , ... September 04, 2015 ... ... dollar-wise they all pale in comparison to settlements under the Stark physician self-referral ... an upcoming Sept. 17 webinar from Atlantic Information Services, Inc. (AIS), will ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... a Labor Day offer that cannot be passed up. FiltersFast.com, will ship ... necessary air and water filtration product replacements. Take advantage of this promotion now ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Friday night, Chicago ... hosting Generation Rescue’s A Night of Hope event supporting families affected by autism, raising ... Rowena and Joe Salas, joined together at the Oscar Swan Inn to support the ...
Breaking Medicine News(10 mins):Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2
... , , , ... were considered prized possessions of the Emperors of China and were personally ... Monarchs of Europe and discerning people all over the world. This luxurious ... most popular dog breeds today. , , ...
... , KUALA LUMPUR, Malaysia, Aug. 26 ... privatization within the healthcare service provision and upgrading of existing ... services has also received positive impetus from growing promotion of ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , According ...
... Health Group Inc. ("AIM" or the "Company") (TSXV - AHG), ... net income for the three month period ended June 30, ... $118,223 in the same period in 2008. At the same ... quarter-over-quarter basis. The Company also announced that revenues increased 102% ...
... is the GlaxoSmithKline statement in response to the FDA,s Early Communication about ... stands firmly behind the safety and efficacy of alli . ... that there is no evidence that alli causes liver damage. ... cases on liver injury associated with the use of orlistat/alli. Any routine ...
... restart production of missing protein , TUESDAY, Aug. 25 ... appears to jump-start the production of a crucial protein ... researchers report. , The treatment so far is only ... debilitating and ultimately fatal disease, but scientists are hopeful ...
... with coronary artery disease-induced congestive heart failure or heart ... radiation therapy for treatment of prostate cancer have an ... in the August 26 issue of JAMA . ... options available for treatment, including the use of brachytherapy ...
Cached Medicine News:Health News:Royal Canin Continues to Pioneer the Pet Food Industry With an Exclusive Diet Just for Pugs 2Health News:Frost & Sullivan: Growing Healthcare Tourism in Malaysia 2Health News:Frost & Sullivan: Growing Healthcare Tourism in Malaysia 3Health News:AIM Health Group Inc. announces June 30, 2009 financial results showing continued improvement in quarterly profits 2Health News:AIM Health Group Inc. announces June 30, 2009 financial results showing continued improvement in quarterly profits 3Health News:AIM Health Group Inc. announces June 30, 2009 financial results showing continued improvement in quarterly profits 4Health News:AIM Health Group Inc. announces June 30, 2009 financial results showing continued improvement in quarterly profits 5Health News:Experimental Treatment Could Fight Muscular Dystrophy 2Health News:Hormone therapy for prostate cancer patients with heart conditions linked to increased death risk 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: